We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Epizyme Achieves $4 Million Pre-Clinical Milestone Payment in Eisai Strategic Partnership
News

Epizyme Achieves $4 Million Pre-Clinical Milestone Payment in Eisai Strategic Partnership

Epizyme Achieves $4 Million Pre-Clinical Milestone Payment in Eisai Strategic Partnership
News

Epizyme Achieves $4 Million Pre-Clinical Milestone Payment in Eisai Strategic Partnership

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Epizyme Achieves $4 Million Pre-Clinical Milestone Payment in Eisai Strategic Partnership"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Under the terms of the agreement, Epizyme may earn more than $200M in research, development and sales milestones and up to double-digit royalties. Additionally, Eisai will fund 100 percent of R&D through human proof-of-concept, at which point Epizyme has the right to opt into a profit share and co-commercialization arrangement for the United States.

Robert Copeland, Ph.D., EVP and CSO of Epizyme, said: "EZH2 is a very promising oncogenic target with strong validation in genetically-defined cancers, including subtypes of lymphoma and solid tumors with high unmet therapeutic needs. It has been less than a year since we began our partnership with Eisai. The significant progress we have made in this time affirms Epizyme's ability to discover and pursue small molecule histone methyltransferase inhibitors as personalized therapeutics for genetically-defined cancer patients."

The HMT class of epigenetic enzymes contains 96 members, many of which have strong genetic associations with cancer and other serious diseases. Targeting HMTs with potent and selective small molecule inhibitors offers an innovative therapeutic approach to controlling pathways of disease-causing gene expression.

Advertisement